Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2007

Novartis Inks Pact with Adenosine Therapeutics to Develop Drugs for Diabetes and Asthma

  • Novartis acquired an option to Adenosine Therapeutics’ (ATL) A2B receptor antagonist program. Adenosine Therapeutics will continue to develop the program for the oral treatment of type 2 diabetes, asthma, and other disorders.

    "Collaborating with Novartis allows Adenosine Therapeutics to complement its internal research capabilities with those of this well-respected leader in the pharmaceutical industry and provides robust financing to take the program forward into clinical development,” points out Robert S. Capon, CEO and co-founder of Adenosine Therapeutics.

    In addition to the drug candidates developed by ATL, Novartis obtained an exclusive option to the U.S. patent that covers the use of A2B receptor antagonists for the treatment of diabetes and related diseases.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »